EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection

Freddy Frost, José Miguel Rivera-Caravaca, Gregory Y H Lip

Journal of Thrombosis and Thrombolysis · 2025

DOI: 10.1007/s11239-025-03096-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Freddy Frost und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpoo…. Hauptthemen laut MEDLINE: COVID-19, Anticoagulants, COVID-19 Drug Treatment, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb- Pfizer alliance, Bristol Myers Squibb– Pfizer alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long COVID (LC) or post-acute sequelae of SARS-CoV-2 infection (PASC) is defined as ongoing, relapsing or new symptoms/conditions persisting after an acute COVID-19 infection. Given the potential role of oral anticoagulants (OAC) in treating thrombotic sequelae of LC/PASC, we investigated whether prevalent OAC use at the time of acute COVID-19 infection was associated with reduced development of LC/PASC. Retrospective cohort study within the TriNetx network. The primary cohort was defined as adults with a confirmed diagnosis of COVID-19. We defined OAC users as those who had received OACs (either direct-acting OACs [DOACs] or vitamin K antagonists [VKA]) in the preceding 3-months and non-users as those without OAC use within the previous 12-months. The primary outcome was a composite of 9 features associated with LC/PASC We identified 38,409 DOAC users, 19,243 VKA users, and 2,329,771 non-OAC users with acute COVID-19 infection. After successful propensity score matching (PSM), we found an increased risk of LC/PASC features in those receiving DOAC compared to non-OAC (HR [95% CI] 1.50 [1.35 to 1.68], p < 0.0001), and in VKA users compared to non-OACs (HR [95% CI] 1.98 [1.78 to 2.20], p < 0.0001), while DOAC users were at reduced risk compared to VKA users (HR [95% CI] 0.71 [0.62 to 0.81], p < 0.0001). We found no evidence that prevalent OAC at the time of acute COVID-19 infection was associated with reduced risk of LC/PASC. Further work is needed to understand whether there is a role for OAC therapy in the management of LC/PASC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AnticoagulantsCOVID-19 Drug TreatmentThrombosisHumansRetrospective StudiesMaleFemaleMiddle AgedAdministration, OralAgedPost-Acute COVID-19 SyndromeSARS-CoV-2AdultTime FactorsRisk FactorsVitamin K

Substanzen

AnticoagulantsVitamin K

Autor:innen und Institutionen

  • Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Faculty of Nursing, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB- Arrixaca), CIBERCV, Murcia, Spain.
  • Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. gregory.lip@liverpool.ac.uk.
  • Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. gregory.lip@liverpool.ac.uk.

Förderung

  • Bristol Myers Squibb- Pfizer alliance
  • Bristol Myers Squibb– Pfizer alliance

Zitieren

APA

Frost, F., Rivera-Caravaca, J. M., & Lip, G. Y. H. (2025). The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03096-0

Vancouver

Frost F, Rivera-Caravaca JM, Lip GYH. The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03096-0

BibTeX
@article{Frost2025,
  author = {Frost, Freddy and Rivera-Caravaca, José Miguel and Lip, Gregory Y H},
  title = {The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2025},
  doi = {10.1007/s11239-025-03096-0}
}
Kostenlos starten →